GlassScriptPhysician profile
Jeffrey I Barke
NPI 1437109758
$2,113.63
in general payments reported to CMS, 2019-2025
31 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $427 · 2021: $453 · 2022: $151 · 2023: $201 · 2024: $318 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.28 | 2019-2025 | |
| Novo Nordisk INC | $218.47 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $180.22 | 2019-2021 | |
| Lilly USA, LLC | $144.95 | 2019-2024 | Jardiance, Zepbound, Trulicity |
| Exact Sciences Corporation | $117.46 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $98.95 | 2022-2025 | |
| Abbott Laboratories | $88.46 | 2023-2024 | Freestyle Libre 3 |
| Allergan, INC. | $68.51 | 2019-2020 | |
| Sanofi Pasteur INC. | $65.04 | 2019-2021 | |
| Cleerly, INC. | $60.79 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Takeda Pharmaceuticals U.S.A., INC. | $57.57 | 2019-2022 | |
| Genentech USA, INC. | $57.14 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.71 | 2022 | |
| Pfizer INC. | $54.61 | 2019-2023 | |
| Amgen INC. | $52.44 | 2021-2024 | Otezla, Repatha |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $45.78 | 2021-2025 | Airsupra |
| Alfasigma USA, INC. | $43.13 | 2021 | |
| Daiichi Sankyo INC. | $42.32 | 2019-2021 | |
| Antares Pharma, INC. | $42.09 | 2019-2020 | |
| Medtronic USA, INC. | $27.70 | 2019 | |
| Glaxosmithkline, LLC. | $25.34 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.51 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.98 | 2021 | |
| Lucid Diagnostics INC. | $23.21 | 2025 | |
| Hikma Pharmaceuticals USA | $17.76 | 2024 | Ryaltris |
| Tolmar, INC. | $17.52 | 2025 | Jatenzo |
| Dynavax Technologies Corporation | $16.21 | 2019 | |
| Gilead Sciences, INC. | $15.19 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.81 | 2022 | |
| Currax Pharmaceuticals LLC | $14.44 | 2025 | Contrave |
| Bardy Diagnostics, INC. | $10.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Barke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.